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Bromazepam is a benzodiazepine generally used for a number of medical reasons, it is an intermediate-acting 
tranquilizer, prescribed for the treatment of moderate to severe anxiety and panic attacks for the short-term 
treatment of insomnia. It has been widely used in psychiatry disorders for four decades, with selective 
anxiolytic, anticonvulsant, myorelaxant and hypnotic actions. It acts on the central neural system as an inhibitor 
of the neurotransmitter gamma aminobutyric acid (GABA).  
The biotransformation from solid into absorbable form depends on its dissolution in organic liquids; therefore, 
dissolution tests became an essential parameter to determine the properties of pharmaceutical formulations in 
order to predict their quality. The quality of pharmaceutical formulations is important in financial and ethical 
terms because it is directly associated with the patient’s health. Thus, there is a real need for the development of 
dissolution tests able to predict in vivo physiological behavior. 
 
The present study is focused on minimizing limitations and developing a simple, precise, accurate and economic 
method for estimation of Bromazepam in tablet dosage forms. 
 
Dissolution test is a standardized method for measuring the rate of drug release from a dosage form. For 
dissolution medium 0.1 M HCl was chosen, in volume of 500 ml, at 37ºC, performed on ERWEKA DT 700, 
apparatus 2 (paddle), with 75 rpm for 45 minutes. An analytical method for Dissolution by using High 
Performance Liquid Chromatography technique was validated for content of Bromazepam and the validation 
was carried out on Shimadzu Nexera HPLC system. To optimize chromatographic parameters several mobile 
phase compositions were tested. A satisfactory separation, good peak symmetry and optimal retention time was 
obtained with mobile phase consisting a mixture of methanol, acetonitrile and potassium dihydrogen phosphate 
buffer (KH₂PO₄) (pH 7.0; 11.33g/l KH₂PO₄) in ratio of 45:5:50 (v/v/v) that was set at flow rate of 1.0 ml/min 
was found to be optimum and further optimized by adjusting pH 7.0 by adding KOH 0.5M. A LiChrospher RP 
Select B column (125 × 4.0 mm, 5μm) is used as stationary phase with temperature of column oven, 50ºC.  
 
The proposed method is simple, rapid, accurate, precise, and specific in relation to interference of excipients. Its 
chromatographic run time of 3.50 min allows the analysis of a large number of samples in short period of time. 
Therefore, it is suitable for the routine analysis of Bromazepam in pharmaceutical dosage forms.  
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